Drugs / Recombinant Human Interferon a-2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02593968 | Sep 2015 → Sep 2016 | human papilloma virus infection | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2006-10-18 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗
Yallaferon® ("Recombinant Human Interferon α-2b gel") has been approved for an additional indication for use in the treatment of cervicitis by the SFDA of China. |
| 2005-09-07 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Yallaferon® leespharm.com ↗
Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that Yallaferon® (Recombinant Human Interferon α-2b gel) has been approved for an additional indication for use in the treatment of herpes zoster by the SFDA of China. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-01 | Lee's Pharmaceutical Limited | Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon® leespharm.com ↗ |
| 2021-12-29 | Lee's Pharmaceutical Limited | Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award leespharm.com ↗ |
| 2006-10-18 | Lee's Pharmaceutical Limited | New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗ |
| 2005-12-20 | Lee's Pharmaceutical Limited | Completion of the Study of Yallaferon® in Cervicitis Patients leespharm.com ↗ |
| 2005-09-07 | Lee's Pharmaceutical Limited | New Indication Approved for Yallaferon® leespharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Interferon a-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02593968 ↗ |
| Known as | Yallaferon | “a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in...” NCT02593968 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interferon Alpha-2b Gel (Yallaferon®)” NCT02593968 ↗ |